Back to Search
Start Over
Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial
- Source :
- The Lancet; July-August 2024, Vol. 404 Issue: 10450 p341-352, 12p
- Publication Year :
- 2024
-
Abstract
- Intensified systemic chemotherapy has the highest primary cure rate for advanced-stage, classical Hodgkin lymphoma but this comes with a cost of severe and potentially life long, persisting toxicities. With the new regimen of brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone (BrECADD), we aimed to improve the risk-to-benefit ratio of treatment of advanced-stage, classical Hodgkin lymphoma guided by PET after two cycles.
Details
- Language :
- English
- ISSN :
- 01406736 and 1474547X
- Volume :
- 404
- Issue :
- 10450
- Database :
- Supplemental Index
- Journal :
- The Lancet
- Publication Type :
- Periodical
- Accession number :
- ejs66988572
- Full Text :
- https://doi.org/10.1016/S0140-6736(24)01315-1